How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,503 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians Full Text available with Trip Pro

Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians Opportunities From the Greater Use of Generic Medications | Annals of Internal Medicine | American College of Physicians '); } '); })(); Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org (...) to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 5 January 2016 Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians Free Niteesh K. Choudhry, MD, PhD; Thomas D. Denberg

2015 American College of Physicians

22. A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Adult patients, >/=18 years of age Diagnosis of diabetes mellitus, type 2 Patients treated with stable sulfonylurea monotherapy or sulfonylurea plus metformin combination (...) A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2012 Clinical Trials

23. Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

number of saved studies (100). Please remove one or more studies before adding more. Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02314637 Recruitment Status : Completed First (...) Posted : December 11, 2014 Results First Posted : January 2, 2015 Last Update Posted : August 20, 2015 Sponsor: Mitsubishi Tanabe Pharma Corporation Information provided by (Responsible Party): Mitsubishi Tanabe Pharma Corporation Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type 2 Diabetes for 52 weeks

2014 Clinical Trials

24. Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.

adding more. Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin. (ZODIAC-39) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02133118 Recruitment Status : Completed First Posted : May 7, 2014 Last Update Posted : March 17, 2015 Sponsor: Medical Research Foundation (...) Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin. Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2014 Clinical Trials

25. QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia

of saved studies (100). Please remove one or more studies before adding more. QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02298803 Recruitment Status : Completed First Posted : November (...) QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

26. Comparative safety and effectiveness of the sodium glucose co-transporter 2 (SGLT2) inhibitors compared to sulfonylureas or insulin in the management of type 2 diabetes: a systematic review and network meta-analysis

Comparative safety and effectiveness of the sodium glucose co-transporter 2 (SGLT2) inhibitors compared to sulfonylureas or insulin in the management of type 2 diabetes: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2016 PROSPERO

27. Safety and efficacy of sulfonylureas compared to drugs with low risk of hypoglycaemia

Safety and efficacy of sulfonylureas compared to drugs with low risk of hypoglycaemia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing (...) text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured

2016 PROSPERO

28. Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Recruitment Status : Completed First Posted : January 16, 2013 Results First Posted : October 14, 2015 Last Update Posted : January 25, 2016 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy (...) for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes mellitus Stable dose of sulfonylurea that is at least 50% of the maximum approved dose per the local label for at least 3 months prior to the first study visit Have an HbA1c value of ≥7.5% and ≤9.5%, as determined by the central laboratory draw performed at the first study visit Accept continued treatment

2013 Clinical Trials

29. Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea

studies (100). Please remove one or more studies before adding more. Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01964950 Recruitment Status : Completed First Posted : October 17, 2013 (...) Results First Posted : April 13, 2017 Last Update Posted : April 13, 2017 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to examine the safety and efficacy of long-term combination therapy with alogliptin (Nesina) and sulfonylurea in participants with type 2 diabetes mellitus who responded inadequately to treatment with sulfonylurea in addition to diet therapy and exercise therapy. Condition

2013 Clinical Trials

30. A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) The safety and scientific validity of this study

2012 Clinical Trials

31. Diabetes Treatment With Glucobay in Combination With Sulfonylurea

With Glucobay in Combination With Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01613105 Recruitment Status : Completed First Posted : June 6, 2012 Last Update Posted : June 26, 2013 Sponsor: Bayer Information provided by: Bayer Study Details Study Description Go to Brief Summary (...) Diabetes Treatment With Glucobay in Combination With Sulfonylurea Diabetes Treatment With Glucobay in Combination With Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diabetes Treatment

2012 Clinical Trials

32. Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"

Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01660386 Recruitment Status : Unknown Verified

2012 Clinical Trials

33. Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients

Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) . ClinicalTrials.gov Identifier: NCT01885013 Recruitment Status : Completed First Posted : June 24, 2013 Last Update Posted : January 1, 2016 Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Information provided by (Responsible Party): Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Study Details Study Description Go to Brief Summary: This is a phase II comparative randomized clinical trial. Eligible patients will be randomized (1:1) to: Arm A: Myocet plus Cyclofosfamide

2013 Clinical Trials

34. Lipodystrophy, Generalized (Diagnosis)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

35. Erythroderma (Generalized Exfoliative Dermatitis) (Overview)

Erythroderma (Generalized Exfoliative Dermatitis) (Overview) Erythroderma (Generalized Exfoliative Dermatitis): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi1vdmVydmlldw== processing > Erythroderma (Generalized Exfoliative Dermatitis) Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Overview Background Exfoliative dermatitis (ED) is a definitive term that refers to a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Exfoliative dermatitis is characterized by erythema and scaling involving

2014 eMedicine.com

36. Erythroderma (Generalized Exfoliative Dermatitis) (Treatment)

Erythroderma (Generalized Exfoliative Dermatitis) (Treatment) Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management: Medical Care, Consultations, Diet Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi10cmVhdG1lbnQ= processing > Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Treatment Medical Care Patients presenting acutely with exfoliative dermatitis (ED) often require admission for inpatient management because their total body functions (including intake and output) can require monitoring

2014 eMedicine.com

37. Lipodystrophy, Generalized (Treatment)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

38. Lipodystrophy, Generalized (Overview)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

39. Lipodystrophy, Generalized (Follow-up)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

40. Erythroderma (Generalized Exfoliative Dermatitis) (Follow-up)

Erythroderma (Generalized Exfoliative Dermatitis) (Follow-up) Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management: Medical Care, Consultations, Diet Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi10cmVhdG1lbnQ= processing > Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Treatment Medical Care Patients presenting acutely with exfoliative dermatitis (ED) often require admission for inpatient management because their total body functions (including intake and output) can require monitoring

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>